Santarus (SNTS)
Drug/indication: Uceris for ulcerative colitis
Approval decision date: Oct. 16
Impax Labs (IPAX)
Drug/indication: IPX066 for Parkinson's disease
Approval decision date: Oct. 19
United Therapeutics (UTHR)
Drug/indication: Oral Remodulin for pulmonary arterial hypertension
Approval decision date: Oct. 26
Cornerstone Therapeutics (CRTX)
Drug/indication: Lixivaptan for hyponatremia
Approval decision date: Oct. 29
Drug/indication: MDV3100 for prostate cancer
Approval decision date: Nov. 21 Exelixis (EXEL)
Drug/indication: Cabozantinib for medullary thyroid cancer
Approval decision date: Nov. 29
Alexza Pharmaceuticals (ALXA)
Drug/indication: Adasuve for agitation due to schizophrenia
Approval decision date: Dec. 21
This is Alexza's third attempt at Adasuve approval. Aegerion Pharmaceuticals (AEGR)
Drug/indication: Lomitapide for dyslipidemia/hypercholesterolemia
Approval decision date: Dec. 28 Biogen Idec (BIIB)
Drug/indication: BG-12 for multiple sclerosis
Approval decision date: Dec. 28
BG-12 would be Biogen's first pill for multiple sclerosis. NuPathe (PATH)
Drug/indication: Zelrix for migraine
Approval decision date: Jan. 16, 2013
This is NuPathe's second attempt at Zelrix approval. Sanofi and Isis Pharmaceuticals (ISIS)
Drug/indication: Kynamro for hypercholesterolemia
Approval decision date: Jan. 29, 2013
Raptor Pharmaceutical (RPTP)
Drug/indication: RP103 for cystinosis
Approval decision date: Jan. 30, 2013. Celgene (CELG)
Drug/indication: Pomalidomide for multiple myeloma
Approval decision date: Feb. 10, 2013. Dynavax (DVAX)
Drug/indication: Heplisav for hepatitis B prevention
Approval decision date: Feb. 24, 2013 Sources: Company reports, TheStreet research, BioMedTracker.com --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: tips@thestreet.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
